HROW
Harrow, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-34/100
Last price
30.35
▼ 0.23 (0.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
30.58
Day high
30.90
Day low
29.85
Volume
421.49K
Market cap
$1.14B
P/E (TTM)
—
52W range
28.54 – 54.85
Trailing performance
Returnvs SPY
1W
-3.34%
-5.3%
1M
-21.25%
-22.4%
3M
-32.66%
-37.2%
6M
-14.34%
-32.5%
YTD
-38.06%
-52.3%
1Y
-33.19%
-49.6%
3Y
+111.20%
+29.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HROW open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.50K
Net buying
Buy transactions
5
26.75K shares
Sell transactions
1
11.25K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
5.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | SHOJAEI AMIR Officer |
CONVERSION | 11.25K | $404.55K | Direct |
| Aug 14, 26 | SHOJAEI AMIR Officer |
SELL | 11.25K | $450.00K | Direct |
| May 18, 26 | SILVERNAIL LAUREN P Director |
BUY | 1.00K | $31.00K | Direct |
| May 18, 26 | GRAVES ADRIENNE L Director |
BUY | 1.00K | $31.07K | Direct |
| May 14, 26 | BAUM MARK L Chief Executive Officer |
BUY | 10.00K | $302.00K | Direct |
| May 14, 26 | BOLL ANDREW R President |
BUY | 3.50K | $104.65K | Direct |
| Mar 4, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 198.57K | $7.85M | Indirect |
| Feb 27, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 5.00K | $270.90K | Indirect |
| Jan 6, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 20.00K | $1.07M | Indirect |
| Dec 12, 25 | BAUM MARK L Chief Executive Officer |
CONVERSION | 180.00K | $711.00K | Direct |
| Dec 12, 25 | BOLL ANDREW R President |
CONVERSION | 60.00K | $237.00K | Direct |
| Jul 21, 25 | BAUM MARK L Chief Executive Officer |
CONVERSION | 600.00K | $4.72M | Direct |
| Jun 10, 25 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 30.20K | $923.83K | Indirect |
| Jun 4, 25 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 4.80K | $144.02K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAUM MARK L |
Chief Executive Officer | 3.00M | Purchase |
BOLL ANDREW R |
President | 814.68K | Purchase |
GRAVES ADRIENNE L |
Director | 1.00K | Purchase |
OPALEYE MANAGEMENT, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SAHAREK JOHN P |
Chief Executive Officer | 467.39K | Conversion of Exercise of derivative security |
SHOJAEI AMIR |
Officer | 0 | Conversion of Exercise of derivative security |
SILVERNAIL LAUREN P |
Director | 1.00K | Purchase |
Fundamentals
Market cap$1.14B
Enterprise value$1.35B
Revenue (TTM)$275.59M
Gross profit$201.96M
EBITDA$17.71M
Net income$-37.23M
EPS (TTM)$-0.98
Free cash flow$-5.49M
Total cash$85.32M
Total debt$300.74M
Book value / share$0.41
Shares outstanding37.49M
Float28.93M
Short % of float22.23%
Dividend yield0.00%
Beta (5Y)0.19
Valuation & profitability ratios
Trailing P/E—
Forward P/E10.95
PEG ratio—
Price / sales—
Price / book74.75
EV / revenue4.91
EV / EBITDA76.37
Gross margin73.28%
Operating margin-15.58%
Profit margin-13.51%
Return on equity-116.07%
Return on assets-0.45%
Debt / equity2,025.89
Current ratio2.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $272.30M | $199.61M | $130.19M | $88.59M | +36.4% |
| Operating revenue | $271.91M | $198.62M | $117.45M | $88.59M | +36.9% |
| Cost of revenue | $67.93M | $49.24M | $39.64M | $25.38M | +38.0% |
| Gross profit | $204.37M | $150.37M | $90.55M | $63.21M | +35.9% |
| Research & development | $20.94M | $12.23M | $6.65M | $3.05M | +71.2% |
| Selling, general & admin | $152.91M | $129.06M | $83.09M | $58.24M | +18.5% |
| Total operating expense | $173.85M | $141.29M | $89.74M | $61.29M | +23.0% |
| Operating income | $30.52M | $9.07M | $811.00K | $1.92M | +236.3% |
| Net interest income | -$24.18M | -$22.79M | -$21.32M | -$7.24M | -6.1% |
| Pre-tax income | -$1.37M | -$17.32M | -$23.71M | -$14.01M | +92.1% |
| Tax provision | $3.77M | $161.00K | $701.00K | $75.00K | +2,242.2% |
| Net income | -$5.14M | -$17.48M | -$24.41M | -$14.09M | +70.6% |
| Net income to common | -$5.14M | -$17.48M | -$24.41M | -$14.09M | +70.6% |
| Basic EPS | -0.14 | -0.49 | -0.75 | -0.51 | +71.4% |
| Diluted EPS | -0.14 | -0.49 | -0.75 | -0.51 | +71.4% |
| EBIT | $22.81M | $5.47M | -$2.39M | -$6.77M | +317.3% |
| EBITDA | $42.49M | $20.00M | $9.95M | -$3.10M | +112.4% |
| Basic shares | 36.71M | 35.65M | 32.62M | 27.62M | +3.0% |
| Diluted shares | 36.71M | 35.65M | 32.62M | 27.62M | +3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $72.93M | $47.25M | $74.08M | $96.27M | +54.4% |
| Cash & short-term investments | $72.93M | $47.25M | $82.77M | $101.86M | +54.4% |
| Accounts receivable | $110.89M | $116.37M | $36.26M | $6.25M | -4.7% |
| Inventory | $13.52M | $10.70M | $10.87M | $6.54M | +26.4% |
| Total current assets | $211.75M | $189.65M | $139.48M | $118.26M | +11.7% |
| Property, plant & equipment | $11.04M | $12.29M | $10.31M | $11.00M | -10.1% |
| Goodwill & intangibles | $176.69M | $187.03M | $162.38M | $26.17M | -5.5% |
| Total assets | $399.48M | $388.97M | $312.16M | $157.38M | +2.7% |
| Total current liabilities | $96.30M | $91.34M | $49.34M | $18.63M | +5.4% |
| Long-term debt | $243.18M | $219.54M | $185.88M | $104.17M | +10.8% |
| Total debt | $251.98M | $228.83M | $193.22M | $112.23M | +10.1% |
| Total liabilities | $347.39M | $319.67M | $241.75M | $130.14M | +8.7% |
| Retained earnings | -$156.52M | -$151.38M | -$133.90M | -$109.49M | -3.4% |
| Shareholder equity | $52.45M | $69.65M | $70.77M | $27.59M | -24.7% |
| Working capital | $115.45M | $98.31M | $90.14M | $99.63M | +17.4% |
| Net tangible assets | -$124.24M | -$117.38M | -$91.61M | $1.43M | -5.8% |
| Shares issued | 37.23M | 35.62M | 35.17M | 29.90M | +4.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.14M | -$17.48M | -$24.41M | -$14.09M | — | +70.6% |
| Depreciation & amortisation | $19.68M | $14.54M | $12.34M | $3.67M | — | +35.4% |
| Stock-based compensation | $12.50M | $17.62M | $15.70M | $7.97M | — | -29.0% |
| Change in working capital | $185.00K | -$44.63M | -$7.13M | -$5.57M | — | +100.4% |
| Operating cash flow | $43.86M | -$22.20M | $3.84M | $1.71M | — | +297.6% |
| Capital expenditure | -$1.10M | -$38.67M | -$152.55M | -$7.77M | — | +97.2% |
| Investing cash flow | -$5.46M | -$33.16M | -$152.55M | -$1.74M | — | +83.5% |
| Share buybacks | — | — | — | $0 | -$11.00M | — |
| Dividends paid | — | — | — | $0 | -$127.00K | — |
| Financing cash flow | -$12.72M | $28.53M | $126.53M | $54.14M | — | -144.6% |
| Free cash flow | $42.76M | -$60.88M | -$148.71M | -$6.07M | — | +170.2% |
| End cash position | $72.93M | $47.25M | $74.08M | $96.27M | — | +54.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $70.66M | $44.20M | $89.09M | $71.64M | $63.74M | +59.9% |
| Operating revenue | $70.57M | $44.13M | $89.01M | $71.50M | $63.66M | +59.9% |
| Cost of revenue | $20.30M | $17.16M | $18.47M | $17.71M | $16.23M | +18.3% |
| Gross profit | $50.36M | $27.05M | $70.62M | $53.93M | $47.51M | +86.2% |
| Research & development | $8.07M | $5.89M | $11.72M | $3.32M | $2.87M | +36.9% |
| Selling, general & admin | $53.30M | $43.23M | $43.31M | $35.86M | $33.23M | +23.3% |
| Total operating expense | $61.37M | $49.13M | $55.03M | $39.18M | $36.10M | +24.9% |
| Operating income | -$11.01M | -$22.08M | $15.59M | $14.75M | $11.41M | +50.1% |
| Net interest income | -$6.26M | -$5.50M | -$5.19M | -$6.04M | -$6.41M | -13.9% |
| Pre-tax income | -$17.27M | -$27.58M | $10.40M | $1.02M | $5.00M | +37.4% |
| Tax provision | $0 | $25.00K | $3.77M | $0 | $0 | -100.0% |
| Net income | -$17.27M | -$27.60M | $6.63M | $1.02M | $5.00M | +37.4% |
| Net income to common | -$17.27M | -$27.60M | $6.63M | $1.02M | $5.00M | +37.4% |
| Basic EPS | -0.46 | -0.74 | 0.18 | 0.03 | 0.14 | +37.8% |
| Diluted EPS | -0.46 | -0.74 | 0.17 | 0.03 | 0.13 | +37.8% |
| EBIT | -$11.01M | -$22.08M | $15.58M | $7.06M | $11.40M | +50.1% |
| EBITDA | -$4.82M | -$16.30M | $20.55M | $11.96M | $16.31M | +70.4% |
| Basic shares | 37.54M | 37.23M | 36.81M | 37.15M | 36.79M | +0.8% |
| Diluted shares | 37.54M | 37.23M | 38.98M | 38.88M | 38.85M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83.89M | $94.64M | $72.93M | $74.29M | $52.96M | — | -11.4% |
| Cash & short-term investments | $83.89M | $94.64M | $72.93M | $74.29M | $52.96M | — | -11.4% |
| Accounts receivable | $118.56M | $101.26M | $110.89M | $77.60M | $78.82M | — | +17.1% |
| Inventory | $16.91M | $16.50M | $13.52M | $12.83M | $11.55M | — | +2.5% |
| Total current assets | $229.31M | $226.38M | $211.75M | $177.60M | $154.89M | — | +1.3% |
| Property, plant & equipment | $10.35M | $10.72M | $11.04M | $11.35M | $11.67M | — | -3.4% |
| Goodwill & intangibles | $177.16M | $182.44M | $176.69M | $174.12M | $178.48M | — | -2.9% |
| Total assets | $416.82M | $419.54M | $399.48M | $363.07M | $345.03M | — | -0.6% |
| Total current liabilities | $102.17M | $91.44M | $96.30M | $65.40M | $248.88M | — | +11.7% |
| Current debt | — | — | — | — | $183.62M | $108.31M | — |
| Long-term debt | $292.38M | $292.09M | $243.18M | $242.87M | $38.48M | — | +0.1% |
| Total debt | $300.74M | $300.67M | $251.98M | $251.87M | $231.25M | — | +0.0% |
| Total liabilities | $401.97M | $391.19M | $347.39M | $316.41M | $295.73M | — | +2.8% |
| Retained earnings | -$201.40M | -$184.13M | -$156.52M | -$163.15M | -$164.17M | — | -9.4% |
| Shareholder equity | $15.20M | $28.71M | $52.45M | $47.02M | $49.65M | — | -47.0% |
| Working capital | $127.14M | $134.94M | $115.45M | $112.20M | -$93.99M | — | -5.8% |
| Net tangible assets | -$161.96M | -$153.73M | -$124.24M | -$127.10M | -$128.82M | — | -5.3% |
| Shares issued | 37.48M | 37.27M | 37.23M | 37.03M | 36.71M | — | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.27M | -$27.60M | $6.63M | $1.02M | $5.00M | +37.4% |
| Depreciation & amortisation | $6.18M | $5.78M | $4.97M | $4.90M | $4.90M | +7.1% |
| Stock-based compensation | $3.79M | $3.84M | $3.80M | $3.27M | $875.00K | -1.3% |
| Change in working capital | -$2.76M | $8.74M | -$11.63M | -$1.69M | -$13.09M | -131.5% |
| Operating cash flow | -$9.76M | -$8.99M | $8.41M | $16.59M | -$803.00K | -8.5% |
| Capital expenditure | -$534.00K | -$18.20M | -$372.00K | -$225.00K | -$293.00K | +97.1% |
| Investing cash flow | -$534.00K | -$18.20M | -$4.73M | -$225.00K | -$293.00K | +97.1% |
| Financing cash flow | -$466.00K | $48.91M | -$5.04M | $4.96M | -$12.67M | -101.0% |
| Free cash flow | -$10.29M | -$27.20M | $8.04M | $16.36M | -$1.10M | +62.2% |
| End cash position | $83.89M | $94.64M | $72.93M | $74.29M | $52.96M | -11.4% |
Options analytics
Put / call volume
2.75
Put-heavy session
Put / call open interest
0.24
Positioning, not flow
Max pain
22.00
-27.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+120.0%
Puts bid over calls
Call volume
185
Contracts, this expiry
Put volume
509
Contracts, this expiry
Heaviest call OI
40.00
431 contracts
Heaviest put OI
20.00
82 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.24 | -0.46 | -91.7% |
| Mar 2026 | -0.33 | -0.74 | -124.2% |
| Dec 2025 | 0.48 | 0.27 | -43.7% |
| Sep 2025 | 0.29 | 0.33 | +13.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.32 | 4 | $99.07M | +38.3% |
| Next quarter | 1.00 | 3 | $137.06M | +53.8% |
| Current year | 0.43 | 3 | $350.15M | +28.6% |
| Next year | 2.77 | 4 | $536.32M | +53.2% |
Analyst targets & ownership
Mean target$65.00
High target$88.00
Low target$45.00
Implied upside114.17%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy0 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders15.38%
Held by institutions58.58%
Institutions holding295
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.56
-3.83% from price
SMA 20
33.04
-8.16% from price
SMA 50
36.82
-17.58% from price
SMA 100
37.78
-19.66% from price
SMA 200
40.21
-24.52% from price
EMA 12
31.82
-4.63% from price
EMA 26
33.78
-10.14% from price
EMA 50
35.75
-15.11% from price
RSI (14)
26.2
Oversold
MACD (12,26,9)
-1.95
Hist -0.13
ATR (14)
1.26
4.14% of price
Realised vol 30D
37.5%
Annualised
Bollinger upper
36.96
20, 2σ
Bollinger lower
29.13
20, 2σ
50 / 200 cross
Death
36.82 vs 40.21
Trend bias
Below 200
-24.52%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.40
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
37.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-47.0%
Peak to trough
Max drawdown 5Y
-71.2%
Peak to trough
ATR 14
1.26
4.14% of price
Beta (reported)
0.19
5Y monthly, from filing
Short interest
Shares short
7.49M
Prior 6.36M
Change vs prior
+17.8%
Shorts adding
% of float
22.23%
Heavily shorted
% of shares out
19.98%
Against total outstanding
Days to cover
15.2
Crowded exit
Float
28.93M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 21, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 13, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| May 12, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 7, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Mar 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 18, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 4, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Mar 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:5
Split dateFeb 8, 2013
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-04
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-03
Periodic Financial Reports
10-Q · 2026-05-11
Proxy Statements
DEFA14A · 2026-04-24
Headlines
Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
MT Newswires · 2d ago
Harrow Closes Acquisition of TYRVAYA®
GlobeNewswire · 2d ago
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
GlobeNewswire · 7d ago
Leerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price Target
MT Newswires · 28d ago
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Insider Monkey · 34d ago
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Insider Monkey · 48d ago
Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study
MT Newswires · 48d ago
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
GlobeNewswire · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.